I also asked a few questions regarding; managements estimated range of current EV (I think worded that way they can actually give an answer as to what they believe is a correct range and still not contravene their non-disclosure with Deloitte - I asked for a with and without CoVid estimate), whether any of the the knowledge gained through CoVid research could be applied to AIDs and whether any pursuit of partnering on other compounds in the library might be forthcoming.  Obviously none were addressed.  I might pursue this later but I am going to see if IR might be a tiny bit proactive and reach out on their own, they have the questions and the contact info.  I will share if I receive any feedback.